Flow cytometric chemosensitivity assay as a predictive tool of early clinical response in acute lymphoblastic leukemia. - Wikidata - awgldk - TriplyDB

Flow cytometric chemosensitivity assay as a predictive tool of early clinical response in acute lymphoblastic leukemia.

Flow cytometric chemosensitivity assay as a predictive tool of early clinical response in acute lymphoblastic leukemia.

http://www.wikidata.org/entity/Q37416851

about

Current status of methods to assess cancer drug resistance.Flow cytometric chemosensitivity assay using JC‑1, a sensor of mitochondrial transmembrane potential, in acute leukemia.Clinical impact of in vitro cellular drug resistance on childhood acute lymphoblastic leukemia in Taiwan.

P2860

Q34779180-0F2CB0C9-AB27-42DE-A935-E83D85D49F22 Q39079802-24E9BE91-2503-4744-90FC-9A1DFE9B6B4B Q50259972-F8FAF458-71C7-415E-B51A-C45D5A69BD22

P2860

Flow cytometric chemosensitivity assay as a predictive tool of early clinical response in acute lymphoblastic leukemia.

http://www.wikidata.org/entity/Q37416851

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Flow cytometric chemosensitivi ...... acute lymphoblastic leukemia.

@en

Flow cytometric chemosensitivi ...... acute lymphoblastic leukemia.

@nl

type

label

Flow cytometric chemosensitivi ...... acute lymphoblastic leukemia.

@en

Flow cytometric chemosensitivi ...... acute lymphoblastic leukemia.

@nl

prefLabel

Flow cytometric chemosensitivi ...... acute lymphoblastic leukemia.

@en

Flow cytometric chemosensitivi ...... acute lymphoblastic leukemia.

@nl

P1433

Q37416851-EA45911D-58D7-48BF-B239-6973CD0F17C5

P1476

Q37416851-D39247B1-E4EE-4F58-B3A5-62D8D047BD81

P2093

Q37416851-61F0C70F-226F-4B99-B347-3F078A057ADD

Q37416851-8B60A7DA-2775-4246-8152-662F48365146

Q37416851-98F02AAD-C1F0-474C-B7F5-4F6E7B41B8BE

Q37416851-AFECBD0C-7F04-476A-9B02-9B70BCCB06D8

Q37416851-C3D5020A-19C3-4035-8C09-D857A73E1CBA

Q37416851-E41B1CFB-9A2E-4EB2-A385-39F4ECB219A7

P2860

Q37416851-077DDE4F-CA99-442F-9626-EB77B8E5EF95

Q37416851-19115047-D93F-43A8-8793-CEC21C69CDA5

Q37416851-1A4F5ECC-55D3-4258-9D8C-2EE03B5B96F5

Q37416851-1E2C0BC3-5F8E-48B1-891C-140D6856B0C6

Q37416851-287DE410-6F6F-4D92-BEDC-8526C4D41F35

Q37416851-30F50481-CB58-4BD0-8970-8F4CFD5BBC1D

Q37416851-3B9CA573-8E39-4D39-840A-59475C6293DA

Q37416851-3D9A6E8E-7F0F-4D05-A0B4-92411B5F2D5C

Q37416851-5105EA53-CB10-4A1C-BE21-54EC669598EF

Q37416851-53E020A6-AD25-4CA2-A36F-C0E96D39ADA1

P304

Q37416851-1B250ADD-3EEB-404A-8B47-38148CF6578E

P31

Q37416851-16C3E450-9B45-4311-A176-18FFF61C0666

P356

Q37416851-A7FCB8BD-69C3-40A4-873A-B9EA128CD95C

P433

Q37416851-4DBD3D9B-F132-4D89-BB22-1475E09F8C31

P478

Q37416851-5FE8FA3D-92A0-4B79-B4DA-31AB1809987E

P577

Q37416851-FBC2B62C-C405-4456-9868-5A2F2E16B8F2

P5875

Q37416851-8FE8FDAA-7B44-47C4-9F5F-B7714C07A7B0

P698

Q37416851-8B1F199C-C55C-48AA-8283-FB6F63BB43ED

P921

Q37416851-39D9C6D8-4B9C-441B-B3A2-68068B5A2015

P932

Q37416851-DACB4923-AF42-4205-89DC-DA40A5E50A42

P356

P1433

Pediatric Blood & Cancer

P1476

Flow cytometric chemosensitivi ...... acute lymphoblastic leukemia.

@en

P2093

Faith Galderisi

http://www.w3.org/2001/XMLSchema#string

James Huang

http://www.w3.org/2001/XMLSchema#string

Ju Li

http://www.w3.org/2001/XMLSchema#string

Linda Stork

http://www.w3.org/2001/XMLSchema#string

Motomi Mori

http://www.w3.org/2001/XMLSchema#string

Solange Mongoue-Tchokote

http://www.w3.org/2001/XMLSchema#string

P2860

Prediction of response to drug therapy of cancer. A review of in vitro assays.

Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.

Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.

Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia.

Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia.

Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance.

In vitro assays for chemotherapy sensitivity.

Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.

Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia.

P304

543-550

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PBC.22119

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P577

2009-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26269673

http://www.w3.org/2001/XMLSchema#string

P698

19499583

http://www.w3.org/2001/XMLSchema#string

P921

P932

2775428

http://www.w3.org/2001/XMLSchema#string